WO2014103488A1 - 経鼻インフルエンザワクチン組成物 - Google Patents
経鼻インフルエンザワクチン組成物 Download PDFInfo
- Publication number
- WO2014103488A1 WO2014103488A1 PCT/JP2013/078721 JP2013078721W WO2014103488A1 WO 2014103488 A1 WO2014103488 A1 WO 2014103488A1 JP 2013078721 W JP2013078721 W JP 2013078721W WO 2014103488 A1 WO2014103488 A1 WO 2014103488A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spray
- influenza
- vaccine composition
- administered
- nasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a nasal mucosal spray administration type influenza vaccine composition.
- Influenza is an acute respiratory infection caused by influenza virus, and it is prevalent every year especially in winter. In addition, it may become a global pandemic, often leading to serious death. Influenza is known to have a certain preventive effect by inoculating an influenza vaccine, and it is widely inoculated before the epidemic period.
- influenza vaccines that are inoculated subcutaneously with inactivated protein components of influenza virus antigens are approved in Japan, and this split vaccine is currently used as a seasonal influenza vaccine.
- Such a subcutaneous inoculation vaccine is highly effective in preventing the severity of influenza such as pneumonia, but it has a low ability to induce antibodies in the upper respiratory tract mucosa, which is the site of influenza virus infection, and it can be said that its protective effect is sufficient. Absent.
- Patent Document 1 discloses a nasal influenza vaccine containing an adjuvant, and it has been shown that the ability to induce immunity is improved by including an adjuvant. There is concern about toxicity.
- nasal vaccine as a next-generation influenza vaccine is desired from the conventional influenza vaccine inoculated subcutaneously or intramuscularly.
- problems for practical use such as how to suppress the toxicity of the adjuvant used in the drug.
- An object of the present invention is to use a nasal mucosal spray administration type which is effective with a small amount of antigen and has little side effect reaction without using an adjuvant, using an influenza virus inactivated whole particle vaccine which has been previously approved and used as an antigen. It is providing the influenza vaccine composition, its manufacturing method, and the prevention method of influenza.
- a nasal mucosal spray administration gel base comprising a carboxyvinyl polymer treated by applying a shearing force from the outside in order to add spray performance is not affected by influenza virus. It has been found that the ability to induce immunity to humans can be enhanced without using an adjuvant by combining with an activated whole particle vaccine, and the present invention has been completed. That is, the present invention is as follows.
- [1] comprising a gel base containing (i) whole particles inactivated by influenza virus, and (ii) a carboxyvinyl polymer treated with an external shearing force to add spray performance,
- a nasal mucosal spray administration type influenza vaccine composition characterized by not containing an adjuvant.
- influenza virus inactivated whole particles of (i) are 1 to 500 ⁇ g HA / mL per vaccine virus strain.
- [4] Carboxyvinyl treated with an external shear force to add (1) formulation particle size distribution range, (2) spray density uniformity, and / or (3) injection angle control as spray performance
- the nasal mucosal spray administration type influenza vaccine composition according to any one of [1] to [3], wherein a spray administration gel base containing a polymer is used.
- the preparation average particle size is in the range of 30 ⁇ m to 80 ⁇ m, and the particle size distribution is in the range of 10 ⁇ m to 100 ⁇ m, 80% or more
- the spray density is a uniform full cone with no bias
- the preparation average particle size is in the range of 40 ⁇ m to 70 ⁇ m, and the particle size distribution is in the range of 10 ⁇ m to 100 ⁇ m, 90% or more
- the spray density is a uniform full cone with no bias
- the nasal mucosal spray-administered influenza vaccine composition according to any one of [1] to [7], which uses a spray-administered gel base containing a carboxyvinyl polymer that has been treated by applying a shearing force from the outside.
- the nasal mucosal spray-administered influenza vaccine composition according to any one of [1] to [8] can be sprayed from each nostril to the intranasal mucosa to a subject in need thereof
- a method of preventing influenza comprising administering using a device.
- influenza virus inactivated whole particles are used as an active ingredient, an effective immune response is induced with a smaller amount of antigen without using an adjuvant, and no nasal agent has fewer side effects since no adjuvant is used.
- a mucosal spray-administered influenza vaccine composition can be provided, and an influenza epidemic can be dealt with accurately.
- the nasal mucosal spray administration type influenza vaccine composition of the present invention contains a nasal mucosal spray administration gel base composed of a carboxyvinyl polymer processed by applying an external shearing force in order to add spray performance. By spreading and staying in the mucous membrane for a long time, an effective immune response can be induced with a smaller amount of antigen.
- the antigenicity of virus-inactivated whole particles can be favorably maintained because it can be processed in a short time without applying stress, and effective immunization
- a nasal mucosal spray-administered influenza vaccine composition that induces a response and has few side effects can be provided.
- an adjuvant that is an immunopotentiator is not included, but the upper airway mucosa and systemic immunity induction equivalent to or stronger than those of a composition comprising an influenza virus vaccine and an adjuvant can be provided.
- the present invention is characterized in that an nasal mucosal spray administration gel base composed of a carboxyvinyl polymer treated with an external shearing force to add spray performance and an adjuvant containing influenza virus inactivated whole particles are not used.
- a nasal mucosal spray administration type influenza vaccine composition is provided.
- the “gel base containing a carboxyvinyl polymer treated by applying an external shearing force to add spray performance” used in the present invention refers to, for example, “skin / mucosal adhesive agent disclosed in WO2007 / 123193.
- the term “containing gel base” means a base containing a carboxyvinyl polymer, containing gellan gum as appropriate, and adjusting the viscosity by applying a shearing force from the outside. Such a base is characterized in that it can be adjusted to various viscosities by applying a shearing force from the outside, and can be managed so that the spray angle and spray density from the spray container are suitable for the purpose.
- an upper exhaust airless spray container is used as a multi-dose spray container as described in WO2007 / 123193 and WO2007 / 123207.
- the spray container can be used without any remaining amount in any angle or range of angles, and the object can be achieved.
- the spreadability of influenza virus inactivated whole particles on the nasal mucosa is improved over a wide range for a long time, thereby increasing the immunogenicity of the vaccine. It is.
- Carboxyvinyl polymer which is the raw material for nasal mucosal spray administration, is a hydrophilic polymer obtained by polymerizing acrylic acid as the main component, and limits the pharmaceutical additives normally used to prepare aqueous gels. It can be used without.
- the content of the gel base containing the carboxyvinyl polymer treated by applying an external shearing force in order to add spray performance is 0.1 to 1.0% w / v in terms of the content of carboxyvinyl polymer. Preferably, it is 0.3 to 0.7 w / v%.
- influenza virus inactivated whole particles used in the present invention refer to virus particles purified from a virus suspension obtained by culturing influenza virus while retaining the virus form. Therefore, the influenza vaccine of the present invention means a vaccine excluding split vaccines containing subvirions and subunit vaccines containing purified HA or NA, and is also referred to as whole particle vaccines.
- the whole influenza virus inactivated particles are preferably purified from a virus suspension in the absence of a surfactant and ethers.
- a virus solution containing inactivated influenza virus whole particles purified or concentrated for mixing with a nasal mucosal spray administered gel base is referred to as a virus stock solution.
- the concentration of influenza virus inactivated total particles is preferably 1 to 500 ⁇ g HA / mL (HA conversion) per vaccine virus strain, more preferably 20 to 250 ⁇ g HA / mL (HA conversion). The concentration can be obtained by measuring the concentration of HA protein.
- influenza viruses include all currently known types and subtypes, as well as types and subtypes that will be isolated and identified in the future. In addition, no epidemic has been observed in humans so far, and from the viewpoint of effectively preventing human infection in the future, H1 to 16 excluding H1 and H3 of influenza virus A (ie, H2 And a subtype consisting of a combination of a subtype selected from H4 to 16) and a subtype selected from N1 to 9 is preferred. These subtypes are also referred to as new influenza viruses.
- the subtype is more preferably a combination of a subtype selected from H5, 7 and 9 and a subtype selected from N1-9.
- An influenza virus may be one strain belonging to the same subtype, two or more strains belonging to the same subtype, or two or more strains belonging to different subtypes. May be.
- influenza virus may be a strain isolated from an infected animal or patient, or may be a recombinant virus established by genetic engineering in cultured cells.
- the influenza virus can be cultured by inoculating the virus into the allantoic cavity of chicken eggs and culturing by infecting cultured cells.
- Adjuvant is a general term for substances that have regulatory activities such as enhancement and suppression of immune response, and is an immunopotentiator added to vaccines to enhance the immunogenicity of antigens. Many substances have been studied so far Has been. On the other hand, the use of an adjuvant improves the immune effect of the vaccine, but also has a drawback that side effects such as inflammation may occur. Of course, several candidates are available as adjuvants for nasal vaccines, but there are no adjuvants that have been widely recognized as safe. No nasal vaccine has yet been approved.
- the present inventor can use a nasal mucosal spray administration gel base having excellent spray performance as described above with a high nasal mucosal spread rate for the whole particle vaccine, thereby reducing the amount without using an adjuvant.
- a vaccine with an antigen amount that is effective and has few side effects can be obtained.
- the average particle size of the sprayed product is in the range of 30 ⁇ m to 80 ⁇ m (preferably 40 ⁇ m Device with an appropriate range of 80 to 70 ⁇ m (preferably 90% to a range of 10 ⁇ m to 100 ⁇ m), and a particle size distribution of 80 ⁇ m or more (preferably 90% to a range of 10 ⁇ m to 100 ⁇ m).
- the spray angle from 30 ° to 70 ° (preferably in the range of 40 ° to 60 °), and the spray density to the nose evenly Possible find nasal mucosal spray administration influenza vaccine composition spray administered within, leading to the present invention by discovering their preparation as well as prevention method using the same.
- the vaccine of the present invention may further contain a pharmaceutically acceptable carrier in addition to the influenza virus inactivated whole particles and the nasal mucosal spray administration gel base.
- a pharmaceutically acceptable carrier in addition to the influenza virus inactivated whole particles and the nasal mucosal spray administration gel base.
- carriers commonly used in the production of vaccines and intranasal preparations can be used. Specifically, saline, buffered saline, dextrose, water, glycerin, isotonic aqueous buffer And combinations thereof. Further, a preservative (eg, thimerosal), an isotonic agent, a pH adjuster, a surfactant, an inactivating agent (eg, formalin) and the like are appropriately blended therein.
- the vaccine of the present invention is sprayed into the nasal cavity.
- the vaccine of the present invention can be used to prevent or reduce symptoms of influenza.
- a multi-dose spray nasal container or a sprayable device that does not have a pump function for both nostrils, and generally a sprayable disposable device that does not have a pump function can be used.
- the dosage is determined in consideration of the age, sex, body weight, etc. of the subject, but usually 1 to 150 ⁇ g HA, preferably 5 to 50 ⁇ g HA per one vaccine virus strain is administered as an antigen once or twice or more. can do.
- the administration is preferably performed a plurality of times. In this case, administration is preferably performed with an interval of 1 to 4 weeks.
- a gel base and three types of virus stock solutions were prepared by the following method, and both were mixed as follows to prepare an influenza vaccine composition as an example.
- Influenza vaccine compositions not containing a gel base were prepared with the compositions shown in the following table using the inactivated whole particle antigens used in the above examples as appropriate, and were designated as Comparative Examples 1 to 4. Comparative Example 1
- Example 1 The influenza vaccine composition prepared in Example 1 and Comparative Example 1 was sprayed by nasal spray inoculation of 0.25 mL of one nose in a suitable disposable device for each of four adult volunteers at a 3-week interval for a total of 2 times. The total nostril was 45 ⁇ g HA). Blood was collected over time and nasal washes were collected, and the neutralizing antibody titer against the vaccine strain was measured and evaluated. The results are shown in Table 1 for Example 1 and Table 2 for Comparative Example 1.
- Example 1 vaccine virus stock solution + spray administration gel base
- Comparative Example 1 vaccine inactivated split influenza virus antigen composition not containing gel base
- serum neutralizing antibody Although no increase in antibody titer was observed at 3/4, an increase in antibody titer was observed at 4/4 in Example 1 vaccine, indicating that the level was also significant.
- An increase in the neutralizing antibody titer of the nasal wash was observed in all cases in Example 1 and Comparative Example 1, but it was confirmed that Example 1 had a greater degree.
- Influenza vaccine compositions prepared in Example 2 and Comparative Example 2 were used in appropriate disposable devices, respectively, for adult volunteers, Example 2: 25 people, Comparative Example 2: 24 people, two times at intervals of 3 weeks, and further About half a year later, a total of 3 times, nasal 0.25 mL was inoculated intranasally (both nares total 45 ⁇ g HA). Three weeks after the third inoculation, blood was collected and the nasal wash was collected, and the neutralizing antibody titer against the vaccine strain was measured and evaluated. The results are shown in Table 3.
- Example 2 vaccine virus stock solution + spray administration gel base
- Comparative Example 2 vaccine virus stock solution only
- Example 2 vaccine containing spray administration gel base was compared with Comparative Example 2 vaccine.
- the response was clearly higher. It is said that the immune response in naive humans (infants / children) who are in contact with influenza virus antigens for the first time is difficult to be induced, and the immune response in naive individuals is high, which many healthy adults have never contacted. It can be estimated by examining the antibody response to the vaccine of pathogenic avian influenza virus (H5N1 strain).
- Example 2 vaccine virus stock solution + spray administration gel base
- Example 3 The influenza vaccine compositions prepared in Example 3, Comparative Example 3 and Comparative Example 4 were treated with an appropriate volunteer device and subcutaneous inoculation, respectively, for adult volunteers, Example 3-nasal inoculation: 26 persons, Comparative Example 3- Nasal inoculation: nasal instillation of 0.25 mL of one nose (25 ⁇ g HA / strain / 0.5 mL in total for both nares) and Comparative Example 4 (current vaccine) —subcutaneous inoculation: 38 Once per name, 0.5 mL was inoculated subcutaneously (15 ⁇ g HA / strain / 0.5 mL).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
アジュバントを含まないことを特徴とする経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
本発明の経鼻粘膜スプレー投与型インフルエンザワクチン組成物は、噴霧性能を付加するために外部からせん断力を与えて処理したカルボキシビニルポリマーからなる経鼻粘膜スプレー投与ゲル基剤を含有するため、鼻腔粘膜に広く長く展着・滞留することにより、より少ない抗原量で有効な免疫応答を誘導可能とする。
本発明の経鼻粘膜スプレー投与型インフルエンザワクチン組成物の製造方法によると、ストレスを与えることなく短時間で処理できるためウイルス不活化全粒子の抗原性を良好に維持することができ、有効な免疫応答を誘導し、かつ、副作用の少ない経鼻粘膜スプレー投与型インフルエンザワクチン組成物を提供することができる。
なお、本発明においては、免疫増強剤であるアジュバントを含まないが、インフルエンザウイルスワクチンとアジュバントからなる組成物と同等、またはより強い上気道粘膜及び全身の免疫誘導を提供できる。
噴霧性能を付加するために外部からせん断力を与えて処理したカルボキシビニルポリマーを含有するゲル基剤の含量は、カルボキシビニルポリマーの含量に換算して、0.1~1.0%w/vであり、好ましくは0.3~0.7w/v%である。
本発明のワクチンを用いて、インフルエンザを予防またはその症状を軽減することができる。
投与量は、対象の年齢、性別、体重等を考慮して決められるが、抗原として、1種のワクチンウイルス株当り通常1~150μg HA、好ましくは5~50μg HAを1回または2回以上投与することができる。好ましくは複数回の投与であり、この場合、1~4週間の間隔をあけて投与することが好ましい。
上記のゲル基剤例1とウイルス原液例1~3をそれぞれ(1:1)の比率で混合撹拌し、均質なインフルエンザワクチン組成物実施例1、実施例2および実施例3を得た。各実施例で得られた組成物の組成およびその物性値/噴霧性能を下表に示す。この混合撹拌はウイルス不活化全粒子抗原にストレスを与えることなく、緩やかな混合撹拌で短時間に達成できる。得られたインフルエンザワクチン組成物の成分分量及び物性値並びに適切なデバイスを用いて噴霧した場合の付加された噴霧性能を示す。
実施例1
実施例1および比較例1で調製されたインフルエンザワクチン組成物を適切な使い捨てデバイスにて、それぞれ成人ボランテア4名ずつに3週間間隔で計2回、片鼻0.25mLを経鼻噴霧接種(両鼻孔合計で45μgHA)した。
継時的に採血と鼻腔洗浄液の回収を行い、ワクチン株に対する中和抗体価を測定し評価した。結果を実施例1については表1に、比較例1については表2に示した。
実施例2および比較例2で調製されたインフルエンザワクチン組成物を適切な使い捨てデバイスにて、それぞれ成人ボランテア、実施例2:25名、比較例2:24名ずつに3週間間隔で2回、更に約半年後に追加して計3回、片鼻0.25mLを経鼻噴霧接種(両鼻孔合計で45μgHA)した。
3回接種3週後に採血と鼻腔洗浄液の回収を行い、ワクチン株に対する中和抗体価を測定し評価した。結果を表3に示した。
初めてインフルエンザウイルス抗原に接触するナイーブな状態にあるヒト(幼児・小児)における免疫応答は誘導されにくいとされており、ナイーブな個体における免疫応答は、多くの健康成人が接触したことがない、高病原性鳥インフルエンザウイルス(H5N1株)のワクチンに対する抗体応答を検討することによって推定できると考えられる。
上記結果が示すとおり、ナイーブな被験者でも、実施例2ワクチン(ウイルス原液+スプレー投与ゲル基剤)の経鼻接種を3回行うことにより、血清および鼻腔洗浄液中に高いレベルの中和抗体価が誘導されることが発見された。
実施例3、比較例3および比較例4で調製されたインフルエンザワクチン組成物を適切な使い捨てデバイスおよび皮下接種にて、それぞれ成人ボランテア、実施例3-経鼻接種:26名、比較例3-経鼻接種:25名ずつに3週間間隔で2回、片鼻0.25mLを経鼻噴霧接種(両鼻孔合計で15μgHA/株/0.5mL)並びに比較例4(現行ワクチン)-皮下接種:38名に1回、0.5mLを皮下接種(15μgHA/株/0.5mL)した。
1回接種又は2回接種3週後に採血と鼻腔洗浄液の回収を行い、ワクチン株に対する中和抗体価を測定し評価した。結果を表4に示した。
Claims (10)
- (i)インフルエンザウイルス不活化全粒子、および(ii)噴霧性能を付加するために外部からせん断力を与えて処理したカルボキシビニルポリマーを含有するゲル基剤を含み、
アジュバントを含まないことを特徴とする経鼻粘膜スプレー投与型インフルエンザワクチン組成物。 - (i)のインフルエンザウイルス不活化全粒子が1種のワクチンウイルス株当り1~500μgHA/mLである請求項1に記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- 0.1w/v%から1.0w/v%のカルボキシビニルポリマーを含有する、請求項1または2に記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- 噴霧性能としての、(1)製剤粒度分布範囲、(2)噴霧密度均一性、および/または(3)噴射角度制御を付加するために、外部からせん断力を与えて処理したカルボキシビニルポリマーを含有するスプレー投与ゲル基剤を用いた請求項1~3のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- 0.5w/v%から2.0w/v%のカルボキシビニルポリマーを含有するゲル基剤を用い、噴霧性能としての、(1)製剤粒度分布範囲、(2)噴霧密度均一性、および/または(3)噴射角度制御を付加するために外部からせん断力を与えて処理し、スプレー投与ゲル基剤を得た後、インフルエンザウイルス不活化全粒子を含むウイルス原液とストレスを与えることなく短時間で均一に混和して得られる、請求項1~4のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- カルボキシビニルポリマーを含有する基剤に外部からせん断力を与えて、(1)製剤粒度分布において製剤平均粒子径が30μmから80μmの範囲、粒度分布が10μmから100μmの範囲に80%以上であり、(2)噴霧密度が偏りのない均等なフルコーンとなり、(3)噴射角度が30°から70°の範囲に制御した噴霧性能を付加されたスプレー投与ゲル基剤を用いて製造する請求項1~5のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- カルボキシビニルポリマーを含有する基剤に外部からせん断力を与えて、(1)製剤粒度分布において製剤平均粒子径が40μmから70μmの範囲、粒度分布が10μmから100μmの範囲に90%以上であり、(2)噴霧密度が偏りのない均等なフルコーンとなり、(3)噴射角度が40°から60°の範囲に制御した噴霧性能を付加されたスプレー投与ゲル基剤を用いて製造する請求項1~5のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- ポンプ機能を有しないスプレー可能なデバイスを用いて噴霧投与を可能とするために、(1)製剤粒度分布範囲、(2)噴霧密度均一性、(3)噴射角度制御を付加するために外部からせん断力を与えて処理したカルボキシビニルポリマーを含有するスプレー投与ゲル基剤を用いた請求項1~7のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物。
- 請求項1~8のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物を、それを必要とする対象に、各鼻孔から鼻腔内粘膜に粘稠な製剤を噴霧可能とするデバイスを用いて投与することを含むインフルエンザの予防方法。
- インフルエンザを予防するための、請求項1~8のいずれかに記載の経鼻粘膜スプレー投与型インフルエンザワクチン組成物の使用。
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020157016766A KR102071099B1 (ko) | 2012-12-28 | 2013-10-23 | 경비 인플루엔자 백신 조성물 |
JP2014554202A JP6247639B2 (ja) | 2012-12-28 | 2013-10-23 | 経鼻インフルエンザワクチン組成物 |
EP13867863.6A EP2939692B1 (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
DK13867863.6T DK2939692T3 (da) | 2012-12-28 | 2013-10-23 | Nasal influenzavaccinesammensætning |
SG11201504648TA SG11201504648TA (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
ES13867863T ES2731899T3 (es) | 2012-12-28 | 2013-10-23 | Composición de vacuna nasal contra la gripe |
EP19167809.3A EP3566715A1 (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
RU2015130634A RU2652296C2 (ru) | 2012-12-28 | 2013-10-23 | Композиция назальной вакцины против гриппа |
PL13867863T PL2939692T3 (pl) | 2012-12-28 | 2013-10-23 | Kompozycja szczepionki do nosa przeciw grypie |
SI201331485T SI2939692T1 (sl) | 2012-12-28 | 2013-10-23 | Nazalno cepivo za influenco |
CA2894223A CA2894223C (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
MX2015008380A MX371154B (es) | 2012-12-28 | 2013-10-23 | Composicion nasal de vacuna para la influenza. |
NZ70892213A NZ708922A (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
CN201380068031.4A CN104884086A (zh) | 2012-12-28 | 2013-10-23 | 经鼻流感疫苗组合物 |
BR112015015523-5A BR112015015523B1 (pt) | 2012-12-28 | 2013-10-23 | Composição de vacina nasal para influenza |
US14/653,131 US20160015800A1 (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
AU2013367751A AU2013367751B2 (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
LTEP13867863.6T LT2939692T (lt) | 2012-12-28 | 2013-10-23 | Nazalinė gripo vakcinos kompozicija |
IL239284A IL239284B (en) | 2012-12-28 | 2015-06-08 | Nasal flu vaccine compound |
PH12015501482A PH12015501482B1 (en) | 2012-12-28 | 2015-06-26 | Nasal influenza vaccine composition |
HK15110594.2A HK1209646A1 (en) | 2012-12-28 | 2015-10-28 | Nasal influenza vaccine composition |
US16/200,233 US20190091324A1 (en) | 2012-12-28 | 2018-11-26 | Nasal influenza vaccine composition |
CY20191100681T CY1122372T1 (el) | 2012-12-28 | 2019-06-28 | Συνθεση ρινικου εμβολιου γριπης |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012287900 | 2012-12-28 | ||
JP2012-287900 | 2012-12-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/653,131 A-371-Of-International US20160015800A1 (en) | 2012-12-28 | 2013-10-23 | Nasal influenza vaccine composition |
US16/200,233 Division US20190091324A1 (en) | 2012-12-28 | 2018-11-26 | Nasal influenza vaccine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014103488A1 true WO2014103488A1 (ja) | 2014-07-03 |
Family
ID=51020588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/078721 WO2014103488A1 (ja) | 2012-12-28 | 2013-10-23 | 経鼻インフルエンザワクチン組成物 |
Country Status (27)
Country | Link |
---|---|
US (2) | US20160015800A1 (ja) |
EP (2) | EP2939692B1 (ja) |
JP (1) | JP6247639B2 (ja) |
KR (1) | KR102071099B1 (ja) |
CN (2) | CN110038123A (ja) |
AU (1) | AU2013367751B2 (ja) |
BR (1) | BR112015015523B1 (ja) |
CA (1) | CA2894223C (ja) |
CY (1) | CY1122372T1 (ja) |
DK (1) | DK2939692T3 (ja) |
ES (1) | ES2731899T3 (ja) |
HK (1) | HK1209646A1 (ja) |
HU (1) | HUE044434T2 (ja) |
IL (1) | IL239284B (ja) |
LT (1) | LT2939692T (ja) |
MX (1) | MX371154B (ja) |
MY (1) | MY173503A (ja) |
NZ (1) | NZ708922A (ja) |
PH (1) | PH12015501482B1 (ja) |
PL (1) | PL2939692T3 (ja) |
PT (1) | PT2939692T (ja) |
RU (1) | RU2652296C2 (ja) |
SG (2) | SG10201705190TA (ja) |
SI (1) | SI2939692T1 (ja) |
TR (1) | TR201910293T4 (ja) |
TW (1) | TWI624280B (ja) |
WO (1) | WO2014103488A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
EP3162378A4 (en) * | 2014-06-25 | 2018-01-17 | Toko Yakuhin Kogyo Kabushiki Kaisha | Influenza vaccine nasal vaccination system |
WO2019070019A1 (ja) * | 2017-10-05 | 2019-04-11 | 東興薬品工業株式会社 | 経鼻b型肝炎ワクチン組成物およびその製造方法 |
US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
WO2021002355A1 (ja) | 2019-07-03 | 2021-01-07 | アイリス株式会社 | インフルエンザウイルス感染症を治療するための医薬組成物 |
US11020346B2 (en) | 2014-06-25 | 2021-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Rhinal spray nozzle used for medical syringe |
WO2023120535A1 (ja) * | 2021-12-20 | 2023-06-29 | 東興薬品工業株式会社 | ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用 |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11980643B2 (en) | 2023-08-15 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010114169A1 (en) * | 2009-03-31 | 2010-10-07 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
CN105342982B (zh) * | 2015-11-19 | 2018-08-28 | 上海现代药物制剂工程研究中心有限公司 | 经鼻给药的流感疫苗免疫制剂及其制备方法 |
TW201722472A (zh) * | 2015-11-27 | 2017-07-01 | Nitto Denko Corp | 口腔內投與用疫苗醫藥組合物及口腔內投與用疫苗醫藥組合物之製造方法 |
US20210290715A1 (en) * | 2016-07-29 | 2021-09-23 | Natural Healthcare Co., Ltd. | Anti-influenza virus composition for mucous membranes |
CN113117093B (zh) * | 2019-12-31 | 2024-02-09 | 辽宁成大生物股份有限公司 | 一种适用于鼻粘膜递送流感疫苗的促进剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0338529A (ja) * | 1989-07-04 | 1991-02-19 | Toko Yakuhin Kogyo Kk | 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤 |
WO2007123193A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム |
WO2007123207A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | 流体用容器およびこれを用いたエアレス式流体投与システム |
WO2010114169A1 (en) | 2009-03-31 | 2010-10-07 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
US5215739A (en) * | 1989-04-05 | 1993-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
PT1861120T (pt) * | 2005-03-23 | 2016-08-18 | Glaxosmithkline Biologicals Sa | Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória |
-
2013
- 2013-10-23 MX MX2015008380A patent/MX371154B/es active IP Right Grant
- 2013-10-23 CN CN201910188181.8A patent/CN110038123A/zh active Pending
- 2013-10-23 SG SG10201705190TA patent/SG10201705190TA/en unknown
- 2013-10-23 EP EP13867863.6A patent/EP2939692B1/en active Active
- 2013-10-23 SG SG11201504648TA patent/SG11201504648TA/en unknown
- 2013-10-23 ES ES13867863T patent/ES2731899T3/es active Active
- 2013-10-23 BR BR112015015523-5A patent/BR112015015523B1/pt active IP Right Grant
- 2013-10-23 KR KR1020157016766A patent/KR102071099B1/ko active IP Right Grant
- 2013-10-23 RU RU2015130634A patent/RU2652296C2/ru active
- 2013-10-23 EP EP19167809.3A patent/EP3566715A1/en not_active Withdrawn
- 2013-10-23 LT LTEP13867863.6T patent/LT2939692T/lt unknown
- 2013-10-23 AU AU2013367751A patent/AU2013367751B2/en active Active
- 2013-10-23 CN CN201380068031.4A patent/CN104884086A/zh active Pending
- 2013-10-23 SI SI201331485T patent/SI2939692T1/sl unknown
- 2013-10-23 WO PCT/JP2013/078721 patent/WO2014103488A1/ja active Application Filing
- 2013-10-23 US US14/653,131 patent/US20160015800A1/en not_active Abandoned
- 2013-10-23 DK DK13867863.6T patent/DK2939692T3/da active
- 2013-10-23 CA CA2894223A patent/CA2894223C/en active Active
- 2013-10-23 JP JP2014554202A patent/JP6247639B2/ja active Active
- 2013-10-23 MY MYPI2015701959A patent/MY173503A/en unknown
- 2013-10-23 PT PT13867863T patent/PT2939692T/pt unknown
- 2013-10-23 HU HUE13867863 patent/HUE044434T2/hu unknown
- 2013-10-23 NZ NZ70892213A patent/NZ708922A/en unknown
- 2013-10-23 TR TR2019/10293T patent/TR201910293T4/tr unknown
- 2013-10-23 PL PL13867863T patent/PL2939692T3/pl unknown
- 2013-10-30 TW TW102139274A patent/TWI624280B/zh active
-
2015
- 2015-06-08 IL IL239284A patent/IL239284B/en active IP Right Grant
- 2015-06-26 PH PH12015501482A patent/PH12015501482B1/en unknown
- 2015-10-28 HK HK15110594.2A patent/HK1209646A1/xx unknown
-
2018
- 2018-11-26 US US16/200,233 patent/US20190091324A1/en not_active Abandoned
-
2019
- 2019-06-28 CY CY20191100681T patent/CY1122372T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0338529A (ja) * | 1989-07-04 | 1991-02-19 | Toko Yakuhin Kogyo Kk | 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤 |
WO2007123193A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム |
WO2007123207A1 (ja) | 2006-04-21 | 2007-11-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | 流体用容器およびこれを用いたエアレス式流体投与システム |
WO2010114169A1 (en) | 2009-03-31 | 2010-10-07 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
Non-Patent Citations (2)
Title |
---|
OKA T. ET AL.: "Influenza vaccine: enhancement of immune response by application of carboxy-vinylpolymer.", VACCINE, vol. 8, no. 6, 1990, pages 573 - 576, XP026927094 * |
See also references of EP2939692A4 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9750802B2 (en) | 2009-11-18 | 2017-09-05 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
US10716815B2 (en) | 2011-02-04 | 2020-07-21 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
EP3162378A4 (en) * | 2014-06-25 | 2018-01-17 | Toko Yakuhin Kogyo Kabushiki Kaisha | Influenza vaccine nasal vaccination system |
US11103453B2 (en) | 2014-06-25 | 2021-08-31 | Toko Yakuhin Kogyo Kabushiki Kaisha | Rhinovaccination system of influenza vaccine |
US11020346B2 (en) | 2014-06-25 | 2021-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Rhinal spray nozzle used for medical syringe |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11491219B2 (en) | 2017-10-05 | 2022-11-08 | Tokyo Yakuhin Kogyo Co., Ltd. | Nasal hepatitis B vaccine composition and method for producing same |
JPWO2019070019A1 (ja) * | 2017-10-05 | 2020-10-22 | 東興薬品工業株式会社 | 経鼻b型肝炎ワクチン組成物およびその製造方法 |
WO2019070019A1 (ja) * | 2017-10-05 | 2019-04-11 | 東興薬品工業株式会社 | 経鼻b型肝炎ワクチン組成物およびその製造方法 |
WO2021002355A1 (ja) | 2019-07-03 | 2021-01-07 | アイリス株式会社 | インフルエンザウイルス感染症を治療するための医薬組成物 |
WO2023120535A1 (ja) * | 2021-12-20 | 2023-06-29 | 東興薬品工業株式会社 | ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用 |
US11980643B2 (en) | 2023-08-15 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6247639B2 (ja) | 経鼻インフルエンザワクチン組成物 | |
TWI721949B (zh) | 流行性感冒疫苗經鼻接種系統 | |
JP2023012539A (ja) | 経鼻b型肝炎ワクチン組成物およびその製造方法 | |
EP4026559A1 (en) | Seasonal influenza vaccine capable of inducing virus-specific antibody into nasal cavity | |
RU2773357C2 (ru) | Назальная вакцинная композиция против гепатита b и способ ее получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13867863 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2894223 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239284 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2014554202 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14653131 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20157016766 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/008380 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201503969 Country of ref document: ID Ref document number: 12015501482 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015015523 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2013367751 Country of ref document: AU Date of ref document: 20131023 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013867863 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015130634 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015015523 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150626 |